Zatollah Asemi, Omid Reza Tamtaji, Alireza Milajerdi, Željko Reiner, Ehsan Dadgostar, Elaheh Amirani, Liaosadat Mirsafaei, Mohammad Ali Mansournia, Parisa Maleki Dana, Fatemeh Sadoughi, Jamal Hallajzadeh
Journal: Clinical nutrition ESPEN 2021;40():27-33
PMID: 33183549
OBJECTIVE
This systematic review and meta-analysis of randomized controlled trials (RCTs) was performed to analyze the effects of flaxseed oil supplementation on biomarkers of inflammation and oxidative stress in patients with metabolic syndrome (MetS) and related disorders.
METHODS
Databases including PubMed, Scopus, EMBASE, Web of Science, and Cochrane Central library were searched until January 31, 2019.
RESULTS
14 effect sizes from 12 studies were identified eligible to be included in current meta-analysis. Flaxseed supplementation resulted in a significant reduction in interleukin 6 (IL-6) (WMD: -0.22; 95% CI: -0.43, -0.01) and malondialdehyde (MDA) (WMD: -0.17; 95% CI: -0.31, -0.03) and a significant increase in total antioxidant capacity (TAC) levels (WMD: 137.25; 95% CI: 68.04, 206.47). Flaxseed oil supplementation did not affect other biomarkers of inflammation and oxidative stress.
CONCLUSIONS
Overall, this meta-analysis demonstrated flaxseed oil supplementation decreased IL-6 and MDA levels, and increased TAC, but did not affect other biomarkers of inflammation and oxidative stress among patients with MetS and related disorders. This suggests that flaxseed oil supplementation may have played an indirect role in improved clinical symptoms in diseases with metabolic disorders.
Copyright © 2020 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.